Having trouble accessing articles? Reset your cache.

Lilly, ArQule jockey for best-in-class next-gen Btk inhibitor at ASH

While investors punished ArQule on Phase I data for ARQ 531, the Bruton’s tyrosine kinase inhibitor was tested in a slightly sicker population than Lilly's competing LOXO-305, and each company used different endpoints, making it difficult to declare an early winner.

Read the full 414 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers